



## **Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series**

May 9, 2012

TARRYTOWN, N.Y., May 9, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will participate in the J. P. Morgan Biotech: CEO/CFO Conference Call Series at 10:00 a.m. Eastern Time on Friday, May 11, 2012.

Conference call details are as follows:

Live conference call (US): (888) 889-1309

Live conference call (Outside the US): (773) 756-0161

Passcode: BIOTECH

Replay (US): (888) 568-0720

Replay (Outside the US): (402) 998-1481

Passcode: 1017

A recording of the call will be available for telephone replay until May 17, 2012.

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets two products in the United States, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products. A regulatory application has also been submitted to the FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion. Phase 3 studies are in progress with EYLEA® in a third indication, and with product candidate sarilumab.

Earlier-stage clinical programs are underway with nine additional monoclonal antibodies. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at [www.regeneron.com](http://www.regeneron.com).

### **Contact Information:**

Michael Aberman, M.D.  
Investor Relations  
914.847.7799

[michael.aberman@regeneron.com](mailto:michael.aberman@regeneron.com)

Peter Dworkin  
Corporate Communications  
914.847.7640  
[peter.dworkin@regeneron.com](mailto:peter.dworkin@regeneron.com)

SOURCE Regeneron Pharmaceuticals, Inc.

News Provided by Acquire Media